RESUMEN
OBJECTIVE: To analyze the effect of CytoSorb® on mortality, interleukin levels, vasopressor use and adverse events in patients with sepsis. METHODS: We searched MEDLINE®, Embase and the Cochrane Library for randomized controlled trials and cohort studies that reported the use of CytoSorb® among septic patients. The primary outcome was mortality, and secondary outcomes included the use of vasopressors, levels of inflammatory markers, predicted versus observed mortality, length of stay in the intensive care unit, and adverse events. RESULTS: We included 6 studies enrolling 413 patients, and assessment for risk of bias indicated variations in study quality from high to moderate. The overall mortality rate was 45%, and no significant effect on mortality was found at 28 - 30 days (RR 0.98 [0.12 - 8.25] for the randomized clinical trial and RR 0.74 [0.49 - 1.13] for cohort studies). We did not perform a metanalysis for other outcomes due to the small number of studies found or the lack of data. CONCLUSION: Our study found very low certainty evidence, due to imprecision, risk of bias, and heterogeneity, thereby showing no benefit of CytoSorb® use in terms of mortality at 28 - 30 days. We cannot recommend the use of CytoSorb® in septic or septic shock patients outside clinical trials. Further high-quality randomized trials with a common intervention arm are needed to evaluate the influence of CytoSorb® in this population. PROSPERO REGISTER: CRD42021262219.
Asunto(s)
Sepsis , Choque Séptico , Humanos , Citocinas , Sepsis/terapia , Choque Séptico/terapia , Estudios de Cohortes , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Breast cancer is among the leading cause of cancer-related mortality among Latin American and Caribbean (LAC) women, but a comprehensive and updated analysis of mortality trends is lacking. The objective of this study was to determine the breast cancer mortality rates between 1997 and 2017 for LAC countries and predict mortality until 2030. METHODS: We retrieved breast cancer deaths across 17 LAC countries from the World Health Organization mortality database. Age-standardized mortality rates per 100,000 women-years were estimated. Mortality trends were evaluated with Joinpoint regression analyses by country and age group (all ages, < 50 years, and ≥ 50 years). By 2030, we predict number of deaths, mortality rates, changes in population structure and size, and the risk of death from breast cancer. RESULTS: Argentina, Uruguay, and Venezuela reported the highest mortality rates throughout the study period. Guatemala, El Salvador, and Nicaragua reported the largest increases (from 2.4 to 2.8% annually), whereas Argentina, Chile, and Uruguay reported downward trends (from - 1.0 to - 1.6% annually). In women < 50y, six countries presented downward trends and five countries showed increasing trends. In women ≥ 50y, three countries had decreased trends and ten showed increased trends. In 2030, increases in mortality are expected in the LAC region, mainly in Guatemala (+ 63.0%), Nicaragua (+ 47.3), El Salvador (+ 46.2%), Ecuador (+ 38.5%) and Venezuela (+ 29.9%). CONCLUSION: Our findings suggest considerable differences in breast cancer mortality across LAC countries by age group. To achieve the 2030 sustainable developmental goals, LAC countries should implement public health strategies to reduce mortality by breast cancer.
Asunto(s)
Neoplasias de la Mama , Femenino , Humanos , Persona de Mediana Edad , América Latina/epidemiología , Chile/epidemiología , Argentina , Guatemala/epidemiología , MortalidadRESUMEN
Objective: To describe the clinical and demographic characteristics of patients with acute cerebral infarction treated at a national reference hospital in Peru and determine the risk factors for in-hospital complications. Methods: We conducted a retrospective cohort study including 192 patients with acute ischemic stroke in a national reference hospital in Peru from January to September 2021. Clinical, demographic and paraclinical information was recorded from medical records. We estimated risk ratios and 95% confidence intervals using regression models with Poisson family and robust variance for the bivariate and multivariate model, adjusting for age, sex and risk factors for stroke. Results: At least one in-hospital complication occurred in 32.3% of the patients. The most frequent complications were infectious in 22.4%, followed by 17.7% of neurological complications, with other complications, such as thromboembolism, immobility and miscellaneous, being much less frequent. Regression analysis showed that stroke severity (RR = 1.76; 95%CI:1.09-2.86) and albumin greater than 3.5 mg/dL (RR = 0.53; 95%CI: 0.36-0.79) were independent risk factors for the presence of in-hospital complications. Conclusions: A high rate of in-hospital complications were observed, among which infectious and neurological complications were the most frequent. Stroke severity was a risk factor and albumin greater than 3.5 mg/dL was a protective factor for the incidence of in-hospital complications. These results can serve as a starting point for establishing stroke care systems that consider differentiated flows for the prevention of in-hospital complications.
RESUMEN
ABSTRACT Objective: To analyze the effect of CytoSorb® on mortality, interleukin levels, vasopressor use and adverse events in patients with sepsis. Methods: We searched MEDLINE®, Embase and the Cochrane Library for randomized controlled trials and cohort studies that reported the use of CytoSorb® among septic patients. The primary outcome was mortality, and secondary outcomes included the use of vasopressors, levels of inflammatory markers, predicted versus observed mortality, length of stay in the intensive care unit, and adverse events. Results: We included 6 studies enrolling 413 patients, and assessment for risk of bias indicated variations in study quality from high to moderate. The overall mortality rate was 45%, and no significant effect on mortality was found at 28 - 30 days (RR 0.98 [0.12 - 8.25] for the randomized clinical trial and RR 0.74 [0.49 - 1.13] for cohort studies). We did not perform a metanalysis for other outcomes due to the small number of studies found or the lack of data. Conclusion: Our study found very low certainty evidence, due to imprecision, risk of bias, and heterogeneity, thereby showing no benefit of CytoSorb® use in terms of mortality at 28 - 30 days. We cannot recommend the use of CytoSorb® in septic or septic shock patients outside clinical trials. Further high-quality randomized trials with a common intervention arm are needed to evaluate the influence of CytoSorb® in this population. PROSPERO register: CRD42021262219
RESUMO Objetivo: Analisar o efeito de CytoSorb® na mortalidade, nos níveis de interleucina, no uso de vasopressores e nos eventos adversos em pacientes com sepse. Métodos: Pesquisamos o MEDLINE®, o Embase e a Biblioteca Cochrane em busca de ensaios clínicos randomizados e estudos de coorte que relatassem o uso de CytoSorb® em pacientes com sepse. O desfecho primário foi a mortalidade, e os desfechos secundários incluíram uso de vasopressores, níveis de marcadores inflamatórios, mortalidade prevista versus observada, tempo de internação na unidade de terapia intensiva e eventos adversos. Resultados: Incluímos 6 estudos com 413 pacientes, e a avaliação do risco de viés indicou variações na qualidade do estudo de alta a moderada. A taxa de mortalidade geral foi de 45%, e não foi encontrado efeito significativo na mortalidade entre 28 e 30 dias (risco relativo de 0,98 [0,12 - 8,25] para o ensaio clínico randomizado e de 0,74 [0,49 - 1,13] para estudos de coorte). Não realizamos metanálise para outros desfechos, devido ao pequeno número de estudos encontrados ou à carência de dados. Conclusão: Nosso estudo encontrou evidências de certeza muito baixa, devido à imprecisão, ao risco de viés e à heterogeneidade, demonstrando nenhum benefício no uso de CytoSorb® em termos de mortalidade em 28 a 30 dias. Não podemos recomendar o uso de CytoSorb® em pacientes com sepse ou choque séptico fora dos estudos clínicos. São necessários mais estudos randomizados de alta qualidade com um braço de intervenção comum para avaliar a influência de CytoSorb® nessa população. Registro PROSPERO: CRD42021262219
RESUMEN
Introducción: Se evaluará el uso de la hormona adrenocorticotropa como tratamiento del síndrome de West (síndrome de Lennox-Gastaut) y el tiempo requerido para la progresión hacia la evolución grave. Existen escasos datos sobre esta patología para nuestra población. Material y Métodos: Se trata de una cohorte donde se analizaron 139 historias clínicas de pacientes evaluados en dos unidades de pediatría de la ciudad de Lima entre los años 2000 y 2010. Se incluyeron todos los pacientes que cumplían con los criterios: 1) Espasmos masivos, 2) Retraso en el desarrollo psicomotor y 3) Electroencefalograma que mostró hipsarritmia. Se administró hormona adrenocorticotropa como tratamiento posterior al diagnóstico. El período de seguimiento duró 10 años. Resultados: El cociente de riesgo (CR) de la progresión al Síndrome de Lennox-Gastaut en pacientes que utilizaron la hormona adrenocorticotropa en comparación con aquellos sin hormona adrenocorticotropa fue de 0,45 (IC del 95%: 0,24-0,83, p=0,011). El CR de la progresión al Síndrome de Lennox-Gastaut ajustado para todas las variables estudiadas (edad de inicio, sexo, frecuencia de las crisis, etiología y tiempo desde el diagnóstico hasta el inicio del tratamiento) en pacientes que utilizaban la hormona adrenocorticotropa en comparación con aquellos sin hormona adrenocorticotropa fue de 0,56 (IC del 95%: 0,29 a 0,08; p=0,085). Conclusiones: El uso de la hormona corticotropina en pacientes con síndrome de West podría proteger contra la progresión al síndrome Lennox-Gastaut. Consideramos que esto apoya la evidencia encontrada en poblaciones similares a la nuestra, y creemos que este hallazgo podría ser confirmado con ensayos clínicos.
Background: This paper will evaluate the use of adrenocorticotropic hormone as a therapy modality for West syndrome and the time required for development of the severely progressive form of West syndrome (LGS, Lennox-Gastaut syndrome). There is little data on this condition for our population. Material and Methods: This is a cohort review in which 139 patient records were evaluated in two pediatric units in Lima, Peru; and they were analyzed between 2000 and 2010. All patients who met the following criteria were included in the study: massive spasms, delayed psychomotor development, and hypsarrhythmia in electroencephalogram (EEG) tracing. Adrenocorticotropic hormone was administered to a group of patients as post-diagnosis therapy. The follow-up period for these patients was 10 years. Results: The hazard ratio (HR) for progression to Lennox-Gastaut Syndrome in patients using adrenocorticotropic hormone was 0.45 (95% CI: 0.24-0.83, p= 0.011) compared to those without adrenocorticotropic hormone. Adjusted RR for progression to Lennox-Gastaut Syndrome for all variables studied (age of onset, sex, frequency of seizures, etiology, and time from diagnosis to therapy initiation) in patients who used adrenocorticotropic hormone was 0.56 (95% CI 0.29 to 0.08, P= 0.085) compared with those without adrenocorticotropic hormone. Conclusions: The use of adrenocorticotropic hormone in patients with West syndrome could protect against progression to Lennox-Gastaut syndrome. We consider this supports the evidence found in populations similar to ours, and we believe this finding could be confirmed with clinical trials.
RESUMEN
Introducción: La falta de adherencia a la terapia antihipertensiva contribuye directamente a que los pacientes coexistan con hipertensión, desencadenando mayor riesgo de morbilidad y mortalidad. Así, la falta de adherencia al tratamiento se convierte en una de las principales causas de hipertensión no controlada en la población. Evaluamos los factores asociados a la no-adherencia al tratamiento antihipertensivo en pacientes de cardiología de un hospital de EsSalud en San Juan de Lurigancho-Lima, durante el 2017. Material y Métodos: Estudio analítico-transversal, se incluyeron pacientes que acudieron a consultorio externo de cardiología con historia previa de hipertensión esencial y se excluyeron hipertensión secundaria por otras causas biológicas. Se utilizó el Test de Morisky-Green Morisky Medication Adherence Scale (MMAS-4) para evaluar la no-adherencia al tratamiento antihipertensivo. Resultados: De los 270 participantes de estudio, el 69% (n=185) eran adultos mayores de 65 años, 46% (n=124) varones y el 76% (n=118) tenían pareja estable. Entre los antecedentes clínicos, el 60% (n=122) reportó diagnóstico clínico de hipertensión arterial, el 30% (n=80) de diabetes mellitus tipo II y el 27% (n=73) no-adherencia al tratamiento. Los factores asociados a la no-adherencia de tratamiento fueron sexo masculino (ORa: 0,45, IC95% 0,20-1,04), trabajador independiente (ORa:3,88, IC95% 1,51-9,97), IMC mayor de 30 (ORa:0,23, IC95% 0,07-0,70). Conclusiones: en los pacientes con diagnóstico de hipertensión esencial existen factores de riesgo modificables y no modificables asociados a la no-adherencia al tratamiento. Se deben considerar estos factores para implementar estrategias de tamizaje y focalizar las intervenciones para adherir a los pacientes renuentes a su tratamiento.
Background:Lack of adherence to antihypertensive therapy contributes directly to patients coexisting with hypertension, triggering increased risk of morbidity and mortality. Thus, nonadherence to treatment becomes one of the main causes of uncontrolled hypertension in the population. We evaluated the factors associated with non-adherence to antihypertensive treatment in cardiology patients of an EsSalud hospital in San Juan de Lurigancho-Lima, during 2017. Material and Methods: Analytical-crossover study, patients attending cardiology outpatient clinic with previous history of essential hypertension were included and secondary hypertension due to other biological causes were excluded. The Morisky-Green Morisky Medication Adherence Scale (MMAS-4) was used to assess non-adherence to antihypertensive treatment. Results: Of the 270 study participants, 69% (n=185) were adults older than 65 years, 46% (n=124) were male and 76% (n=118) had a stable partner. Among the clinical history, 60% (n=122) reported clinical diagnosis of arterial hypertension, 30% (n=80) of type II diabetes mellitus and 27% (n=73) non-adherence to treatment. Factors associated with non-adherence to treatment were male sex (ORa: 0.45, 95%CI 0.20-1.04), self-employed (ORa:3.88, 95%CI 1.51-9.97), BMI greater than 30 (ORa:0.23, 95%CI 0.07-0.70). Conclusions: in patients with a diagnosis of essential hypertension there are modifiable and non-modifiable risk factors associated with non-adherence to treatment. These factors should be considered in order to implement screening strategies and target interventions to adhere to treatment in reluctant patients.
RESUMEN
Introducción: Las complicaciones por diabetes tipo 2 (DT2) están incrementando la demanda de servicios especializados en la Seguridad Social Peruana por lo que se torna necesario determinar la magnitud y factores asociados a complicación crónica por DT2 en esta población. Material y Métodos: Estudio transversal-analítico basado en 7875 registros de pacientes con DT2 ≥ 18 años atendidos por consulta externa durante 2016-2017 y notificados en el Sistema de Vigilancia de Diabetes Mellitus de EsSalud. Se evaluaron variables sociodemográficas, clínicas y de comorbilidad mediante un análisis bivariado y un modelo de regresión de Poisson con varianza robusta para determinar la razón de prevalencia a complicación crónica por DT2. Resultados: La complicación microvascular de DT2 estuvo asociado a sexo masculino (RP=1,25; 95%IC: 1,10-1,42; p<0,01), HbA1c>9,0% (RP=1,25; 95%IC: 1,08-1,46; p<0,01), hipertensión arterial (RP=1,30; 95%IC: 1,14-1,49; p<0,01), anemia (RP=1,57; 95%IC: 1,31-1,88; p<0,01), enfermedad tiroidea (RP=1,48; 95%IC: 1,07-2,03; p=0,02), cáncer (RP=1,70; 95%IC: 1,26-2,30; p<0,01) e hígado graso (RP=1,78; 95%IC: 1,28-2,48; p<0,01). El recibir educación para el autocuidado de DT2 mostró asociación negativa con complicación microvascular (RP=0,84; 95%IC: 0,73-0,96; p<0,01). La complicación macrovascular de DT2 estuvo asociado a sexo masculino (RP=1,52; 95%IC: 1,21-1,91; p<0,01), hipertensión arterial (RP=2,72; 95%IC: 1,90-3,91; p<0,01), anemia (RP=1,98; 95%IC: 1,33-2,95; p<0,01) e hígado graso (RP=1,92; 95%IC: 1,03-3,62; p=0,04), mientras que la educación en DT2 mostró asociación negativa (RP=0,47; 95%IC: 0,36-0,61; p<0,01). Conclusiones: La educación en DT2 mostró asociación consistentemente con ausencia de complicación micro y macrovascular, sugiriendo ser un importante factor preventivo. Consideramos necesario evaluar el impacto de la educación mediante diseños apropiados.
Background: Type 2 diabetes (DT2) complications has been increased the demand for specialized services in Peruvian Social Security(EsSalud), so it is necessary to determine the magnitude and factors associated with chronic complication due to DT2 in this population. Material and Methods: Cross-sectional study based on 7875 patients with DT2≥18 years attended by ambulatory care during 2016-2017, notified in the Diabetes Mellitus Surveillance System of EsSalud. Sociodemographic, clinical and comorbidity variables were evaluated using a bivariate analysis and Poisson regression model with robust variance to determine the prevalence ratio of chronic complication due to DT2. Results: The microvascular complication of DT2 was associated with male sex (PR=1.25; 95% CI:1.10-1.42; p<0.01), HbA1c>9.0% (PR=1.25; 95% CI:1.08-1.46; p<0.01), hypertension (PR=1.30; 95% CI: 1.14-1.49; p<0.01), anemia (PR=1.57; 95% CI: 1.31-1.88; p <0.01), thyroid disease (PR=1.48; 95% CI:1.07-2.03; p=0.02), cancer (PR=1.70; 95% CI: 1.26-2.30; p<0.01) and fatty liver (PR=1.78; 95% CI:1.28-2.48; p<0.01). Receiving education for DT2 self-care showed a negative association with microvascular complication (RR=0.84; 95% CI:0.73-0.96; p<0.01). DT2 Ìs macrovascular complication was associated with male sex (PR=1.52; 95% CI:1.21-1.91; p <0.01), arterial hypertension (PR=2.72; 95% CI:1.90-3.91; p <0.01), anemia (PR=1.98; 95% CI:1.33-2.95; p<0.01) and fatty liver (PR=1.92; 95% CI:1.03-3.62; p=0.04), while education in DT2 showed a negative association (PR=0.47; 95% CI: 0.36-0.61; p <0,01). Conclusions: Education in DT2 showed an association consistently with the absence of micro and macrovascular complications, suggesting that it is an important preventive factor. We consider it necessary to evaluate the impact of education through appropriate designs.
Asunto(s)
COVID-19 , COVID-19/diagnóstico , Técnicas de Laboratorio Clínico , Humanos , Inmunoglobulina G , Inmunoglobulina M , Pandemias , Perú , SARS-CoV-2 , Pruebas SerológicasRESUMEN
RESUMEN Introducción. Las complicaciones crónicas por diabetes mellitus tipo 2 (DMT2) elevan la mortalidad y carga de enfermedad en Perú, siendo necesario evaluar su prevalencia y factores asociados. Métodos. Estudio transversal, analítico, en registros de 212 pacientes adultos con DMT2 atendidos por consulta externa en un hospital general del Seguro Social del Perú, durante el año 2017. Resultados. El 71,6% de los pacientes fueron mayores de 60 años y con un tiempo de enfermedad menor de 6 años (40,5%). El 38,7% de los pacientes tuvieron alguna complicación crónica, principalmente nefropatía (48,8%) y neuropatía (45,1%). La hipertensión arterial (52,4%) y la obesidad (43,7%) fueron las comorbilidades más frecuentes en pacientes con complicaciones crónicas. Las complicaciones por DMT2 estuvieron asociadas al número de consultas médicas y monitoreo glicémico. Conclusiones. Existen factores de riesgos asociados a las complicaciones crónicas de DMT2.
ABSTRACT Introduction. The chronic complications of type-2-diabetes mellitus (T2DM) increase mortality and burden of disease in Peru, then it is necessary to evaluate its prevalence and associated factors. Methods. Cross-sectional study in records of 212 adult outpatients with T2DM attended by a social security general hospital in Peru, during 2017. Results. 71,6% of patients were older than 60 years and with a time of illness less than 6 years (40,5%). 38,7% of the patients had any chronic complication, mainly nephropathy (48,8%) and neuropathy (45,1%). Hypertension (52,4%) and obesity (43,7%) were the most frequent comorbidities in outpatients with chronic complications. Complications from DMT2 were associated with the medical consultations and glycemic monitoring. Conclusions. There are risk factors associated to chronic complications of DMT2.
RESUMEN
OBJECTIVE To evaluate the effectiveness of adherence to a multidisciplinary renal health program in reducing mortality and progression to hemodialysis. METHODS We used a database that included patient monitoring (2013-2017), dialysis admissions and all cause of mortality in Peru. Adherence to the program was established by meeting minimum visits during the first year of monitoring. The outcome of interest was hemodialysis admissions or all cause-mortality. Kaplan-Meier curves, Log-Rank test and competing survival analysis methods were used to estimate the differential risk between adherent and non-adherent patients. RESULTS A total of 20,354 participants was evaluated; 54.1% were male, 72.1 years old in average, 2.2 years average follow-up, and 15,279 (75.1%) belonged to the early stages (1 to 3a) of Chronic Kidney Disease. Adherence decreased the risk of renal replacement therapy in 41.0% (HR = 0.59, 95%CI 0.41-0.85) in the low-risk group and mortality in the high-risk group was 31.0% (HR = 0.69, 95%CI 0.57-0.83). CONCLUSIONS The multidisciplinary care strategy with standardized assessments by stage is effective in reducing admission to .0when the patient is identified in early stages and in reducing mortality in advanced stages.
Asunto(s)
Adhesión a Directriz , Fallo Renal Crónico/terapia , Insuficiencia Renal Crónica/terapia , Cumplimiento y Adherencia al Tratamiento/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Estimación de Kaplan-Meier , Fallo Renal Crónico/epidemiología , Masculino , Evaluación de Procesos y Resultados en Atención de Salud , Perú/epidemiología , Evaluación de Programas y Proyectos de Salud , Diálisis Renal , Terapia de Reemplazo Renal , Factores de Riesgo , Análisis de SupervivenciaRESUMEN
RESUMEN Esta revisión presenta la evidencia disponible hasta el mes de junio del 2020 y trata sobre el efecto que tiene la obesidad como posible factor que aumenta la mortalidad en pacientes con diagnóstico por infección por COVID-19. La calidad de la mayoría de los estudios fue buena según la escala de Newcastle Ottawa (mayor o igual a 7/9). Los estudios reportaron seguimientos entre el 6 de febrero hasta el 17 de mayo del 2020. En pacientes con COVID-19, la obesidad fue un factor de riesgo para progresar a mortalidad. Las personas con obesidad deberían ser tratadas como una población de alto riesgo y se deben intensificar las medidas de prevención de contagio antes de la infección y proveer asistencia especializada en casos de confirmados de COVID-19.
ABSTRACT This review presents evidence available up to June 2020 dealing with the effects from obesity as a possible factor increasing mortality in patients diagnosed with COVID-19 infection. Quality for most of the studies was good according to the Newcastle Ottawa scale (7/9 or higher). Studies reported follow-up periods between February 6th up to May 17th, 2020. In patients with COVID-19, obesity was a risk factor for mortality. Obese persons should be treated as a high- risk population, and preventive measures against transmission of the aforementioned infection must be intensified, and specialized assistance must be given to confirmed COVID-19 cases.
RESUMEN
Objetivo: Identificar factores asociados a calidad percibida de atención en la población adulta afiliada al Seguro Social en Salud (EsSalud). Material y métodos: Analizamos la Encuesta Nacional Socioeconómica de Acceso a la Salud de los Asegurados de EsSalud. La calidad percibida fue evaluada en consultorio externo, hospitalización y emergencias. Reportamos razones de medias ajustadas (RMa) estimadas mediante regresión de Poisson múltiple. Resultados: Estar empleado (RMa=0,98; IC95% 0,96-0,99), no conocer los servicios que brinda EsSalud (RMa=0,97; IC95% 0,95-1,00), no recibir información sobre los derechos como usuarios (RMa=0,95; IC95% 0,93-0,98), valorar como bajo el nivel de accesibilidad al EESS (RMa=0,97; IC95% 0,95-0,99) y no sentirse cómodo en el EESS al que acude (RM=0,92; IC95% 0,91-0,94) fueron factores asociados a menor puntaje de calidad percibida en consultorio externo. En hospitalización, tener entre 40-59 años (RMa=0,93; IC95% 0,88-0,97), contar con un índice de riqueza bajo (RMa=0,92; IC95% 0,87-0,97), no haber recibido información sobre los derechos como usuarios (RMa=0,90; IC95% 0,84-0,95) y no sentirse cómodos en el EESS (RMa=0,92; IC95% 0,89-0,96) se asociaron a menor puntuación de calidad. En emergencia, no sentirse cómodo en el EESS (RMa=0,89; IC95% 0,93-1,00) fue el único factor asociado a una menor puntuación de calidad percibida. Conclusiones: Identificamos factores relativos a los usuarios y a la oferta de servicios independientemente asociados a calidad percibida de atención, los cuales pueden ser considerados por los tomadores de decisiones para la mejor gestión de EsSalud.
Objetive: To identify factors associated with perceived quality of care in the adult population affiliated with Social Security Health (EsSalud) Material and methods: We analyzed the National Socioeconomic Survey of Access to Health of the EsSalud Insured. Perceived quality of health care was evaluated in ambulatory care, hospitalization and emergency medical services. We reported adjusted ratios of means (RMa) estimated by multiple Poisson regression. Results: Being employed (RMa=0.98; IC95% 0.96-0.99), not knowing the services provided by EsSalud (RMa=0.97; IC95% 0.95-1.00), not receiving information about right to health (RMa=0.95; IC95% 0.93-0.98), perceiving as low the level of accessibility to the health facility (RMa=0.97; IC95% 0.95-0.99) and not feeling comfortable in the health facility of EsSalud (RM=0.92;IC95% 0.91-0.94) were factors associated with lower scores of perceived quality in ambulatory care. In hospitalization, being between 40-59 years old (RMa=0.93; IC95% 0.88-0.97), having a low wealth index (RMa=0.92; IC95% 0.87-0.97), not having received information about right to health (RMa=0.90; IC95%0.84-0.95) and not feeling comfortable in the health facility of EsSalud (RMa=0.92; IC95% 0.89-0.96) were associated with lower quality score. In emergency, not feeling comfortable in the health facility of EsSalud (RMa=0.89; IC95% 0.93-1.00) was the only factor associated with a lower perceived quality score. Conclusions: We identified factors related to users and service offerings independently associated with perceived quality of care, which can be considered by decision makers for better management of EsSalud.
RESUMEN
OBJECTIVES: To determine the efficacy and safety of the use of cryotherapy, cold knife or thermocoagulation compared to Loop Electrosurgical Excision Procedure (LEEP) for the treatment of cervical intraepithelial neoplasia. METHODS: Systematic review with meta-analysis of randomized controlled trials in women with cervical intraepithelial neoplasia undergoing treatment with cryotherapy, cold knife, or thermo-coagulation compared with LEEP, to estimate its efficacy and safety. The search was conducted on MEDLINE/PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL) and Scopus, until September 2018. RESULTS: The total of 72 studies were identified, of which only 8 studies met the inclusion criteria. The treatment of CIN with cold knife decreases the risk of residual disease compared with LEEP (RR, 0.54, 95%CI, 0.30-0.96, p = 0.04). The management of premalignant lesions with cryotherapy, compared with LEEP, increases the risk of disease recurrence by 86% (RR, 1.86, 95%CI, 1.16-2.97, p = 0.01), increases the risk of infections (RR, 1.17, 95%CI, 1.08-1.28, p < 0.001) and reduces the risk of minor bleeding by 51% (RR, 0.49, 95%CI) %, 0.40-0.59, p ≤ 0.001). CONCLUSIONS: The treatment of premalignant lesions of cervical cancer with cold knife reduces the risk of residual disease. Nevertheless, cryotherapy reduces the risk of minor bleeding in the 24 hours after treatment and increases the risk of recurrence of disease and infections.
Asunto(s)
Conización/métodos , Crioterapia/métodos , Electrocoagulación/métodos , Displasia del Cuello del Útero/cirugía , Neoplasias del Cuello Uterino/cirugía , Femenino , Humanos , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugía , Complicaciones Posoperatorias , Riesgo , Factores de Riesgo , Neoplasias del Cuello Uterino/patología , Displasia del Cuello del Útero/patologíaRESUMEN
RESUMEN Actualmente estamos viviendo una pandemia de enfermedad causada por coronavirus (COVID-19). Un grupo vulnerable de ser infectado por este agente patógeno es el personal de salud. Por ello, el Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) del Seguro Social del Perú (EsSalud) ha emitido recomendaciones clínicas sobre la Evaluación de riesgo y manejo de personal de salud en el contexto de la pandemia de COVID-19, que resumiremos en el presente artículo. Se incluye un flujograma de evaluación y manejo, así como una tabla para determinar el riesgo de presentar infección por COVID-19.
ABSTRACT We are currently experiencing a coronavirus disease (COVID-19) pandemic. A vulnerable group of being infected by this pathogenic agent is health personnel. For this reason, the Health Technology Assessment and Research Institute (IETSI in Spanish) of the Peruvian social insurance (EsSalud) has issued clinical recommendations on risk assessment and management of health care personnel in the context of the COVID-19 pandemic, which we will summarize in this paper. An evaluation and management flow chart are included, as well as a table to determine the risk of developing COVID-19 infection.
RESUMEN
ABSTRACT OBJECTIVES To determine the efficacy and safety of the use of cryotherapy, cold knife or thermocoagulation compared to Loop Electrosurgical Excision Procedure (LEEP) for the treatment of cervical intraepithelial neoplasia. METHODS Systematic review with meta-analysis of randomized controlled trials in women with cervical intraepithelial neoplasia undergoing treatment with cryotherapy, cold knife, or thermo-coagulation compared with LEEP, to estimate its efficacy and safety. The search was conducted on MEDLINE/PUBMED, Cochrane Central Register of Controlled Trials (CENTRAL) and Scopus, until September 2018. RESULTS The total of 72 studies were identified, of which only 8 studies met the inclusion criteria. The treatment of CIN with cold knife decreases the risk of residual disease compared with LEEP (RR, 0.54, 95%CI, 0.30-0.96, p = 0.04). The management of premalignant lesions with cryotherapy, compared with LEEP, increases the risk of disease recurrence by 86% (RR, 1.86, 95%CI, 1.16-2.97, p = 0.01), increases the risk of infections (RR, 1.17, 95%CI, 1.08-1.28, p < 0.001) and reduces the risk of minor bleeding by 51% (RR, 0.49, 95%CI) %, 0.40-0.59, p ≤ 0.001). CONCLUSIONS The treatment of premalignant lesions of cervical cancer with cold knife reduces the risk of residual disease. Nevertheless, cryotherapy reduces the risk of minor bleeding in the 24 hours after treatment and increases the risk of recurrence of disease and infections.
RESUMEN OBJETIVOS Evaluar la eficacia y seguridad del uso de crioterapia, cono frio o termo-coagulación en comparación con el procedimiento de escisión electroquirúrgica en asa (LEEP) para el manejo de neoplasias intraepiteliales cervicales. MÉTODOS Revisión sistemática de ensayos controlados aleatorizados en mujeres con neoplasia intraepitelial cervical en tratamiento con crioterapia, cono frio, o termo coagulación y LEEP, para estimar su eficacia y seguridad. La búsqueda se realizó en MEDLINE/PUBMED, Registro Cochrane Central de Ensayos Controlados (CENTRAL) y Scopus, hasta setiembre de 2018. RESULTADOS Se identificaron 72 estudios, ocho cumplieron los criterios de inclusión. Cono frio disminuyó el riesgo de enfermedad residual en comparación con LEEP (RR 0,54; IC del 95%, 0,30-0,96, p = 0,04). Crioterapia en comparación con LEEP incrementó el riesgo de recurrencia de enfermedad en un 86,0% (RR 1,86; IC del 95%, 1,16-2,97, p = 0,01) con un tiempo de seguimiento de seis a 24 meses, y de infecciones (RR, 1,17; IC del 95%, 1,08-1,28, p < 0,001); pero redujo el riesgo de sangrado menor en un 51,0% (RR 0,49; IC del 95%, 0,40-0,59, p ≤ 0,001). CONCLUSIONES Cono frio reduce el riesgo de enfermedad residual. Sin embargo, la crioterapia reduce el riesgo de sangrado menor en las 24 horas posteriores al tratamiento e incrementa el riesgo de recurrencia de enfermedad y de infecciones.
Asunto(s)
Humanos , Femenino , Neoplasias del Cuello Uterino/cirugía , Crioterapia/métodos , Displasia del Cuello del Útero/cirugía , Conización/métodos , Electrocoagulación/métodos , Complicaciones Posoperatorias , Neoplasias del Cuello Uterino/patología , Riesgo , Factores de Riesgo , Displasia del Cuello del Útero/patología , Recurrencia Local de Neoplasia/cirugía , Recurrencia Local de Neoplasia/patologíaRESUMEN
ABSTRACT OBJECTIVE To evaluate the effectiveness of adherence to a multidisciplinary renal health program in reducing mortality and progression to hemodialysis. METHODS We used a database that included patient monitoring (2013-2017), dialysis admissions and all cause of mortality in Peru. Adherence to the program was established by meeting minimum visits during the first year of monitoring. The outcome of interest was hemodialysis admissions or all cause-mortality. Kaplan-Meier curves, Log-Rank test and competing survival analysis methods were used to estimate the differential risk between adherent and non-adherent patients. RESULTS A total of 20,354 participants was evaluated; 54.1% were male, 72.1 years old in average, 2.2 years average follow-up, and 15,279 (75.1%) belonged to the early stages (1 to 3a) of Chronic Kidney Disease. Adherence decreased the risk of renal replacement therapy in 41.0% (HR = 0.59, 95%CI 0.41-0.85) in the low-risk group and mortality in the high-risk group was 31.0% (HR = 0.69, 95%CI 0.57-0.83). CONCLUSIONS The multidisciplinary care strategy with standardized assessments by stage is effective in reducing admission to .0when the patient is identified in early stages and in reducing mortality in advanced stages.
RESUMEN OBJETIVO Evaluar la efectividad de la adherencia a un programa de salud renal en la reducción de mortalidad y progresión a hemodiálisis. MÉTODOS Utilizamos una base de datos que condensaba el seguimiento de los pacientes (2013-2017), los ingresos a diálisis de los mismos y la mortalidad por todas las causas en Perú. La adherencia al programa se estableció con el cumplimiento de visitas mínimas durante su primer año de seguimiento. La efectividad de la adherencia al programa se midió en términos de debut a hemodiálisis o muerte por todas las causas. Se utilizaron curvas de Kaplan-Meier, test de diferencias en la distribución (Log-Rank test) y métodos de análisis de supervivencia. Los análisis se realizaron utilizando R estudio 3.5.0 RESULTADOS Fueron evaluados 20.354 participantes, 54,1% varones, edad media de 72,1 años, con un seguimiento medio de 2,2 años; 15.279 (75.1%) tuvieron ERC en estadios tempranos (estadio 1 al 3a). La adherencia disminuyó en un 41,0% el riesgo de terapia de reemplazo renal (HR = 0,59; IC95% 0,41-0,85) en el grupo de bajo riesgo y en un 31,0% (HR = 0,69; IC95% 0,57-0,83) la mortalidad en el grupo de alto riesgo. CONCLUSIONES La estrategia de cuidado multidisciplinario con evaluaciones estandarizadas según estadio es efectiva en reducir el ingreso a terapia de reemplazo renal cuando se identifica al paciente en estadios tempranos y en reducir la mortalidad en estadios avanzados.
Asunto(s)
Adhesión a Directriz , Insuficiencia Renal Crónica/terapia , Cumplimiento y Adherencia al Tratamiento/estadística & datos numéricos , Fallo Renal Crónico/terapia , Evaluación de Procesos y Resultados en Atención de Salud , Perú/epidemiología , Evaluación de Programas y Proyectos de Salud , Análisis de Supervivencia , Factores de Riesgo , Diálisis Renal , Terapia de Reemplazo Renal , Estimación de Kaplan-Meier , Fallo Renal Crónico/epidemiologíaRESUMEN
OBJECTIVE: To evaluate the effectiveness of interventions aimed at the prevention of risk factors and incidence of type 2 diabetes in the workers population. METHODS: Systematic review of interventions aimed at adult workers at risk of type 2 diabetes published in Medline, Embase, Web of Science, Central Cochrane Registry of Controlled Trials, and Lilacs. Randomized trials, quasi-experimental research and cohort studies were selected; in English, Spanish and Portuguese; published from 2000 to 2017. Intervention effectiveness was evaluated concerning the incidence of type 2 diabetes and a significant reduction in body weight, or another anthropometric or metabolic parameter. RESULTS: 3,024 articles were generated, of which 2,825 that did not answer the research question were eliminated, as well as 130 that did not evaluate original interventions, 57 carried out outside the workplace and two reviews; so that 10 selected items remained. Interventions based on structured programs previously evaluated and integrated into the workplace had a favorable impact on the reduction of body weight and other risk factors. CONCLUSIONS: The effectiveness of lifestyle interventions for the prevention of type 2 diabetes should be based on structured programs with proven effectiveness and adapted to the workplace, with employer participation in the provision of schedules and work environments.
Asunto(s)
Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/prevención & control , Salud Laboral , Conducta de Reducción del Riesgo , Lugar de Trabajo , Peso Corporal , Femenino , Humanos , Masculino , Factores de Riesgo , Conducta SedentariaRESUMEN
OBJECTIVE: To report the design, methodology and initial results of the National Socioeconomic Survey of Access to Health of the EsSalud Insured. RESULTS: There were interviews in 25,000 homes, surveying 79,874 people, of which 62,659 were affiliated to EsSalud. The insured people are mainly males (50.6%) with a higher technical education level (39.7%). The insured population has mostly independent (95.0%) and own (68.1%) home. Only 34.5% of the insured practice some sport or physical exercise; 14.0% of the population suffers from a chronic disease; 3.5% have diabetes; and 7.1%, arterial hypertension. In the last three months, 35.4% of the members needed medical attention; of these, only 73.1% received health care and the remaining 10.9% were treated in pharmacies or non-formal health care services. RESULTS: The 25,000 homes were interviewed, surveying 79,874 people, of which 62,659 were affiliated to EsSalud. The insured people are mainly males (50.6%) with a higher technical education level (39.7%). The insured population has mostly independent (95.0%) and own (68.1%) home. Only 34.5% of the insured practice some sport or physical exercise; 14.0% of the population suffers from a chronic disease; 3.5% have diabetes; and 7.1%, arterial hypertension. In the last three months, 35.4% of the members needed medical attention; of these, only 73.1% received health care and the remaining 10.9% were treated in pharmacies or non-formal health care services. CONCLUSIONS: This survey is the first performed in the population of EsSalud affiliates, applied at the national level, and has socio-economic and demographic data of the insured, their distribution, risk factors of health, prevalence of health problems and the degree of access to health services.